Primary Biliary Cholangitis — Research Summary
Printed from RareWays (rareways.com.au) on 10 June 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Hsa_circ_0000711 can serve as a novel biomarker for primary biliary cholangitis by promoting disease progression through the regulation of miR-185-5p and NFATc3.
Lu Wenlong et al. — RNA biology (31 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41879109/
- 2.
HPV vaccination intention among unvaccinated international and domestic college students in the U.S.: A cross-sectional survey.
Liu Cheng-Ching et al. — Human vaccines & immunotherapeutics (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41528093/
- 3.
Propagation and scattering of ultrasonic waves in macroscopically anisotropic polycrystalline materials with fiber texture.
Victoria-Giraldo Juan Camilo et al. — Ultrasonics (1 August 2026)
https://pubmed.ncbi.nlm.nih.gov/41812467/
- 4.
Lignocellulolytic fungi to tailor hydrophobic microstructures of biochar for efficient and selective removal of diverse emerging contaminants.
Chen Yu et al. — Bioresource technology (1 June 2026)
https://pubmed.ncbi.nlm.nih.gov/41855997/
- 5.
Longitudinal multi-omics pilot study: Small sample size human model of gut microbiota-mitochondrial metabolic dysregulation in primary biliary cholangitis.
Lou Jing et al. — Microbiological research (1 June 2026)
https://pubmed.ncbi.nlm.nih.gov/41666519/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis
Recruiting — Phase 3 — Ipsen
https://clinicaltrials.gov/study/NCT06016842
- 2.
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Recruiting — Sanford Health
https://clinicaltrials.gov/study/NCT01793168
- 3.
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
Recruiting — Phase 3 — Gilead Sciences
https://clinicaltrials.gov/study/NCT06051617
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Primary Biliary Cholangitis
Primary Biliary Cholangitis is a chronic autoimmune liver disease that slowly destroys the small bile ducts within the liver, leading to bile accumulation, liver damage, and eventually cirrhosis. It predominantly affects women over 40, with a prevalence of approximately 1 in 1,000 in that group. UDCA and obeticholic acid are the main treatments.
Most Recent Research
Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease characterized by autoimmune-mediated destruction of intrahepatic bile ducts. Emerging evidence suggests that circular RNAs (circRNAs) play regulatory roles in autoimmune diseases, but their involvement in PBC remains unclear. This study focused on the hsa_circ_0000711 and its potential mechanism in PBC pathogenesis. The study included 46 PBC patients, 40 healthy controls, and 40 patients with other liver diseases. Human intrahepatic biliary epithelial cells (HiBEpic) were treated with 1 mM glycochenodeoxycholic acid (GCDCA) to establish a PBC cell model. Hsa_circ_0000711 was overexpressed or knocked down using plasmid transfection and siRNA, respectively. Expression levels were analysed by qPCR/Western blot, cell viability by CCK-8, and hsa_circ_0000711-miR-185-5p interaction by luciferase assay. Serum hsa_circ_0000711 levels were significantly higher in PBC patients compared to healthy controls and other liver disease groups (p < 0.0001). GCDCA-treated HiBEpic cells showed increased expression of the E2 subunit of the pyruvate dehydrogenase complex (PDC-E2) and nuclear factor of activated T cells 3 (NFATc3), along with decreased cell viability. Overexpression of hsa_circ_0000711 increased PDC-E2 and NFATc3 expression and worsened cellular injury, while its knockdown reversed these effects. The dual luciferase assay confirmed that hsa_circ_0000711 directly binds to miR-185-5p, suppressing its activity and thereby relieving the repression of NFATc3. Hsa_circ_0000711 promotes PBC progression by sponging miR-185-5p and upregulating NFATc3, leading to bile duct epithelial cell injury. These findings highlight its potential as a novel diagnostic biomarker and therapeutic target for PBC.
Common Questions
What is Primary Biliary Cholangitis?
Primary Biliary Cholangitis is a chronic autoimmune liver disease that slowly destroys the small bile ducts within the liver, leading to bile accumulation, liver damage, and eventually cirrhosis. It predominantly affects women over 40, with a prevalence of approximately 1 in 1,000 in that group. UDCA and obeticholic acid are the main treatments.
How many clinical trials are available for Primary Biliary Cholangitis?
RareWays currently indexes 140 clinical trials for Primary Biliary Cholangitis, of which 32 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Primary Biliary Cholangitis come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Primary Biliary Cholangitis.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.